Oxford BioTherapeutics shared a post on LinkedIn:
” Today, Oxford BioTherapeutics announces a new strategic collaboration with Bristol Myers Squibb to discover and develop next-generation T-cell engagers for solid tumours.
We are pleased to enter this collaboration which leverages Oxford BioTherapeutics proprietary OGAP-Verify discovery platform and drug development capabilities in alignment with Bristol Myers Squibb’s expertise to advance selected novel oncology targets.
This also marks our third major pharma collaboration within the past 12 months and reflects strong validation of our platform’s potential to drive oncology innovation.
Read the full press release here.”
